Last reviewed · How we verify
Ethylenediamine dihydrochloride allergen patch — Competitive Intelligence Brief
marketed
Contact allergen diagnostic agent
Dermatology / Allergy & Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Ethylenediamine dihydrochloride allergen patch (Ethylenediamine dihydrochloride allergen patch) — Allerderm. Ethylenediamine dihydrochloride serves as a contact allergen in patch testing to diagnose delayed-type hypersensitivity reactions and allergic contact dermatitis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ethylenediamine dihydrochloride allergen patch TARGET | Ethylenediamine dihydrochloride allergen patch | Allerderm | marketed | Contact allergen diagnostic agent |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Contact allergen diagnostic agent class)
- Allerderm · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ethylenediamine dihydrochloride allergen patch CI watch — RSS
- Ethylenediamine dihydrochloride allergen patch CI watch — Atom
- Ethylenediamine dihydrochloride allergen patch CI watch — JSON
- Ethylenediamine dihydrochloride allergen patch alone — RSS
- Whole Contact allergen diagnostic agent class — RSS
Cite this brief
Drug Landscape (2026). Ethylenediamine dihydrochloride allergen patch — Competitive Intelligence Brief. https://druglandscape.com/ci/ethylenediamine-dihydrochloride-allergen-patch. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab